Professor Dyfrig Hughes
Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil
- 2003
- Published
Modelling changes in first line antimalarial therapy
Hughes, D. & Hughes, D. A., 1 Sept 2003.Research output: Contribution to conference › Paper
- Published
Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.
Hughes, D., Hughes, D. A. & Walley, T., 1 Jul 2003, In: Clinical Pharmacology and Therapeutics. 74, 1, p. 1-8Research output: Contribution to journal › Article › peer-review
- Published
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Hughes, D. & Hughes, D. A., 1 Jun 2003.Research output: Contribution to conference › Paper
- Published
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Hughes, D. & Hughes, D. A., 1 May 2003.Research output: Contribution to conference › Paper
- 2002
- Published
Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap
Hughes, D., Hughes, D. A. & Bagust, A., 1 Nov 2002.Research output: Contribution to conference › Paper
- Published
Economic evaluation during early (phase II) trials
Hughes, D. & Hughes, D. A., 1 Nov 2002.Research output: Contribution to conference › Paper
- Published
Impact of non-compliance on the cost-effectiveness of pharmaceuticals
Hughes, D. & Hughes, D. A., 1 Nov 2002.Research output: Contribution to conference › Paper
- Published
Patient compliance and pharmacoeconomics
Hughes, D. & Hughes, D. A., 1 Nov 2002.Research output: Contribution to conference › Paper
- Published
The population pharmacokinetics of lapdap
Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Nov 2002.Research output: Contribution to conference › Paper
- Published
Economic impact of poor compliance with pharmaceuticals.
Hughes, D. & Hughes, D. A., 1 Aug 2002, In: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, p. 327-335Research output: Contribution to journal › Article › peer-review